The National Cancer Institute Clinical Trials Planning Meeting to Address Gaps in Observational and Intervention Trials for Cancer-Related Cognitive Impairment
Michelle C Janelsins,Kathleen Van Dyk,Sheri J Hartman,Thuy T Koll,Christina K Cramer,Glenn J Lesser,Debra L Barton,Karen M Mustian,Lynne I Wagner,Patricia A Ganz,Peter D Cole,Alexis Bakos,James C Root,Kristina Hardy,Allison Magnuson,Robert J Ferguson,Brenna C McDonald,Andrew J Saykin,Brian D Gonzalez,Jeffrey S Wefel,David A Morilak,Saurabh Dahiya,Cobi J Heijnen,Yvette P Conley,Alicia K Morgans,Donald Mabbott,Michelle Monje,Stephen R Rapp,Vinai Gondi,Catherine Bender,Leanne Embry,Worta McCaskill Stevens,Judith O Hopkins,Diane St Germain,Susan G Dorsey
DOI: https://doi.org/10.1093/jnci/djae209
2024-09-09
Abstract:Cancer-related cognitive impairment (CRCI) is a broad term encompassing subtle cognitive problems to more severe impairment. CRCI severity is influenced by host, disease, and treatment factors and affects patients prior to, during, and following cancer treatment. The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee (SxQoL SC) convened a Clinical Trial Planning Meeting (CTPM) to review the state of the science on CRCI and to develop both Phase II/III intervention trials aimed at improving cognitive function in cancer survivors with non-central nervous system (CNS) disease and longitudinal studies to understand the trajectory of cognitive impairment and contributing factors. Participants included experts in the field of CRCI, members of the SxQOL SC, patient advocates, representatives from all seven NCI Community Oncology Research Program (NCORP) Research Bases, and the NCI. Presentations focused on the following topics: measurement, lessons learned from pediatric and geriatric oncology, biomarker and mechanism endpoints, longitudinal study designs, and pharmacologic and behavioral intervention trials. Panel discussions provided guidance on priority cognitive assessments, considerations for remote assessments, inclusion of relevant biomarkers, and strategies for ensuring broad inclusion criteria. Three CTPM working groups (longitudinal studies and pharmacologic and behavioral intervention trials) convened for one year to discuss and report on top priorities and to design studies. The CTPM experts concluded sufficient data exist to advance Phase II/Phase III trials utilizing selected pharmacologic and behavioral interventions for the treatment of CRCI in the non-CNS setting with recommendations included herein.